Attachment A - Test Menu Spreadsheet for Sources Sought Announcement.xlsx
XLSX spreadsheet 20 KB Posted
- Attached to
- Q301--Reference Lab Testing
- Solicitation number
- 36C26226Q0581
About this file
This file is a test menu spreadsheet attachment for a Sources Sought market research announcement issued by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 for reference laboratory testing services. The spreadsheet lists 149 clinical laboratory line items (CLINs) organized by test type, including CPT codes, estimated annual quantities, CLIA certification requirements, and pricing fields. Test categories encompass hematologic and oncologic analyses (chromosome analysis, FISH testing, flow cytometry), molecular diagnostics (BCR/ABL detection, JAK2 mutations, FLT3 analysis), immunology services (immunohistochemistry staining, various antibody testing), microbiology testing (bacterial identification, Mycobacterium tuberculosis detection), and specialized assays (mass spectrometry, next-generation sequencing panels). Estimated annual volumes range from 2 to 700 tests depending on the service, with quantities totaling several thousand cumulative annual procedures across the menu. The spreadsheet includes columns for the performing laboratory name, location (city and state), CLIA certification number, and estimated price per test as of April 2026, though pricing fields currently show zero values pending contractor responses. The test menu represents the full scope of laboratory services required to support the Phoenix VA Healthcare System under a prospective contract that would include supplies, packaging, specimen transportation, testing, and reporting as detailed in the associated draft Statement of Work.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| 36C26226Q0581.docx | DOCX document | |
| Attachment B - SOW.doc | DOC document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| CLIN | Service | CPT Code | Estimated Annual Quantity | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test | Estimated Price Per Test (April 2026) (including packaging, supplies, and specimen transportation per SOW) |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | |||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | |||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | |||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | |||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | |||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | |||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | |||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | |||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | |||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | |||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | |||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Certolizumab and Anti-Certolizumab Antibody, DoseASSURE CTZ | 80299, 82397 | 6 | $ - 0 | ||
| 67 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 68 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 69 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 70 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 72 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 73 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 74 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 75 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 76 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 77 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 78 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 79 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 80 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 81 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 82 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 83 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 84 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 85 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 86 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 87 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 88 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 89 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 90 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 91 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 92 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 93 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 94 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 95 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 96 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 97 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 98 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 99 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 100 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 101 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 102 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 103 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 104 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 105 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 106 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 107 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 109 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 110 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 111 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 | ||
| 112 | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies | 81450 | 10 | $ - 0 | ||
| 113 | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum | 86053 | 12 | $ - 0 | ||
| 114 | Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, Serum | 83704 | 2 | $ - 0 | ||
| 115 | Orexin-A/Hypocretin-1, Spinal Fluid | 83519 | 2 | $ - 0 | ||
| 116 | Paraneoplastic Autoantibody Evaluation, Serum | 83519, 86255x9, 86596 | 4 | $ - 0 | ||
| 117 | Peripheral Blood (Bill Only) | 85060 | 20 | $ - 0 | ||
| 118 | Peripheral Blood, TC (Bill Only) | 85007 | 30 | $ - 0 | ||
| 119 | Probe, Each Additional (PCPDS) Bill Only | 88271x2, 88274 | 8 | $ - 0 | ||
| 120 | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone M | 88271x2, 88274, 88291 | 2 | $ - 0 | ||
| 121 | Phospholipase A2 Receptor, Immunofluorescence, Serum | 86255 | 2 | $ - 0 | ||
| 122 | Plasma Cell Proliferative Disorder, FISH, Tissue | Plasma Cell Proliferative Disorder, FISH, Tissue | 2 | $ - 0 | ||
| 123 | Primary Membranous Nephropathy Diagnostic Cascade, Serum | 83520 | 2 | $ - 0 | ||
| 124 | Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor | 81479 | 2 | $ - 0 | ||
| 125 | Sickle Solubility, Blood | 85660 | 2 | $ - 0 | ||
| 126 | Slide Review in Molecular Genetics (Bill Only) | 88381 | 19 | $ - 0 | ||
| 127 | Small Lymphocytic Lymphoma, FISH, Tissue | 88377 | 4 | $ - 0 | ||
| 128 | Soluble Fibrin Monomer, Plasma | 85366 | 2 | $ - 0 | ||
| 129 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 6 | $ - 0 | ||
| 130 | SpecStain, Grp I, Microorganisms (Bill Only) | 88312 | 24 | $ - 0 | ||
| 131 | SpecStain, Grp II, Other (Bill Only) | 88313 | 60 | $ - 0 | ||
| 132 | SpecStain, Grp III, Enzyme (Bill Only) | 88319 | 42 | $ - 0 | ||
| 133 | T-Cell Receptor Gene Rearrangement, Bone Marrow | 81340, 81342 | 2 | $ - 0 | ||
| 134 | T-Cell Receptor Gene Rearrangement, Varies | 81340, 81342 | 10 | $ - 0 | ||
| 135 | Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum | 82728, 83020x2, 83021 | 4 | $ - 0 | ||
| 136 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum | 86255 | 2 | $ - 0 | ||
| 137 | Tissue Processing (Bill Only) | 87176 | 2 | $ - 0 | ||
| 138 | Microsatellite Instability, Tumor | 81301 | 2 | $ - 0 | ||
| 139 | Ustekinumab Quantitation with Antibodies, Serum | 80299, 83520 | 28 | $ - 0 | ||
| 140 | Vedolizumab Quantitation with Reflex to Antibodies, Serum | 80280 | 20 | $ - 0 | ||
| 141 | Beta-Globin Cluster Locus Deletion/Duplication, Blood | 81363 | 2 | $ - 0 | ||
| 142 | Beta-Globin Gene Sequencing, Blood | 81364 | 2 | $ - 0 | ||
| 143 | Neuron-Specific Enolase, CSF | 83520 | 18 | $ - 0 | ||
| 144 | Adrenocorticotropic Hormone, Plasma | 82024 | 100 | $ - 0 | ||
| 145 | Ro52 and Ro60 Antibodies, IgG, Serum | 86235x2 | 12 | $ - 0 | ||
| 146 | JAK2 V617F Mutation Detection, Bone Marrow | 81270 | 22 | $ - 0 | ||
| 147 | Vedolizumab Antibodies, Serum | VEMAB | 8 | $ - 0 | ||
| 148 | Myeloproliferative Neoplasm (MPN), JAK2 V617F with reflex to CALR and MPL | 81270 | 20 | $ - 0 | ||
| 149 | KIT Mutation, Exons 8-11 & 17, Hematologic Neoplasms | 81272 | 2 | $ - 0 |
File details come from the government source that posted it. Updated .